[Renal cancer study activities in Germany. Drug therapy].
Drug therapy of advanced renal cell carcinoma underwent rapid changes. Monotherapeutic, placebo-controlled protocols -- and more recently combinations of different targeted drugs -- dominated the global clinical studies in the past 2 years. The preliminary results are almost encouraging and international investigators, supported by the pharmaceutical industry, were most successful in enrolling patients quickly. The present article reviews the recent German drug study activities and indicates potential future projects.
Rohde
D
D
Urologische Klinik des Klinikums Darmstadt, Akademisches Lehrkrankenhaus der Universität Frankfurt a.M., Darmstadt. detlef.rohde@klinikum-darmstadt.de
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic / Q000639:trends*; D015195:Drug Design; D004341:Drug Evaluation / Q000639:trends*; D005858:Germany; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents